NTLA:NASDAQ
Intellia Therapeutics Inc
US$13.20
arrow_upward
+1.30%(+0.17) 1D
US$13.05
arrow_downward
-1.14% (-0.15)bedtime시간 외 거래
휴장: 4월 28일, 오후 4시 0분 0초 GMT-4 · USD
search
모든 종목 코드
1D
5D
1M
6M
YTD
1Y
5Y
최대
| 종목 코드 | 가격 | 변동 | 변동률(%) |
|---|
insights_autoNTLA의 주요 통계 생성 중...
시가
US$12.82
고가
US$14.16
저가
US$12.72
시가총액
15.59억
평균 거래량
315.18만
거래량
1516.42만
52주 최고가
US$28.25
52주 최저가
US$6.83
EPS
-US$3.81
베타
1.99
유통 주식수
1.18억
직원 수
377
뉴스 기사
웹 소스 기반
프로필
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.
The CRISPR gene editing system was originally invented by Jennifer Doudna, one of Intellia's scientific founders, and Virginijus Šikšnys. The company has entered into a number of different research and development collaborations with leading and emerging biotechnology companies including Novartis, Regeneron, Avencell, SparingVision, Kyverna, and ONK Therapeutics.
Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies. Wikipedia
Intellia Therapeutics Inc에 관한 정보